WebMolecular mechanisms underlying cancer therapeutics-related cardiac dysfunction (CTRCD) induced by anthracyclines, human epidermal growth factor receptor 2 (HER2) … WebMar 1, 2024 · Conclusions and relevance: Using CMR CTRCD as the reference standard, these data suggest that a sequential approach combining echocardiographic 3-D LVEF with 2-D GLS and 2-D GCS may provide a timely diagnosis of CTRCD during routine CTRCD surveillance with greater accuracy than using these measures individually. ...
Cardio-Oncologyの現状と展望
WebJan 26, 2024 · Patients were followed for EF and development of cancer therapy-related cardiac dysfunction (CTRCD) (symptomatic EF reduction >5% or >10% asymptomatic to … WebPatients with 3 CMRs were included in the analysis. Serial quantitative measurements based on CMR were compared using one-way repeated measures analysis of variance (RM-ANOVA). On the basis of cancer therapy-related cardiac dysfunction (CTRCD) observed at the second follow-up, patients were categorized into a CTRCD group and a … duttenhofer\u0027s books cincinnati
一般社団法人日本心エコー図学会
WebAug 2, 2024 · From the distribution of de novo CTRCD and mortality, cancer patients with de novo CTRCD were enriched in orange and green subgroups across multiple time points . However, patients in subgroups purple and orange show the worse mortality within 10 years of cancer therapy initiation ( Fig 3 ), consistent with survival analysis in the combined ... WebAug 25, 2024 · Cancer Therapeutics-Related Cardiac Dysfunction - Insights From Bench and Bedside of Onco-Cardiology. Improvements in the long-term survival of cancer … WebFeb 5, 2024 · Cancer-therapeutics-related cardiac dysfunction (CTRCD) is an important concern in women receiving trastuzumab therapy for HER2+ breast cancer. However, the ability to assess CTRCD risk remains limited. In this retrospective cohort study, we apply three published risk prediction models (Ezaz et al., … in a world of my own alice